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Abstract 
Owing to the better understanding of physiochemical and biological challenges 
associated with the bioactivity of small organic molecules, novel scaffolds are becoming more 
extensively engineered and more highly optimized. Currently, binding specificity is becoming 
intensively investigated and a priority to many drug designers because it reflects the quality of 
scaffolds. In this thesis, we introduce a comparative analysis to benchmark the quality of four 
novel scaffold libraries prepared by the University of Pittsburgh Centers for Chemical 
Methodologies and Library Development (UPCMLD). The bioactivity profiles of these novel 
scaffold libraries, namely UPCMLD09A, UPCMLD02A, UPCMLD16A, and UPCMLD24A, 
were explored and compared with those of two privileged (benzodiazepines and 
dihydropyridines) and two promiscuous (rhodanines and quinolines) scaffold libraries from the 
literature. The approach we implemented is intended to provide an unbiased analysis and 
comparison of novel, privileged and promiscuous scaffold libraries. The results for three of the 
UPCMLD libraries, UPCMLD09A, UPCMLD16A and UPCMLD24A, indicate a comparatively 
high selectivity. Therefore, we suggest that the scaffolds of these libraries could be considered as 
privileged. In contrast, a promiscuous profile for some compounds was observed in one of the 
UPCMLD libraries, UPCMLD02A.  
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1.0  INTRODUCTION 
Many synthetic lead structures in medicinal chemistry projects are commonly designed 
around relatively few specific scaffolds1, in the hope of improving the odds for developing drugs 
that would cure human diseases or at least enhance the quality of life in patients. 
Synthetic scaffolds represent functionalized core structures from which substituents 
branch out. While there are many commercial building blocks available to vary these core 
structures, medicinal chemists are generally conservative and select those with a record of useful 
bioactivity. However, recent efforts to identify novel scaffolds have increased, in part due to the 
challenges of intellectual property protection in a patent space crowded by many generic claims,2 
and in part due to the vast expansion of drug targets that require a broader selection of potential 
modulators.  High throughput screens (HTS) are in particular need of structurally innovative 
chemical collections to increase the quality of the hits.1 Although a number of these novel 
scaffolds are being designed based on accidental chemical discoveries, some of them have been 
more rationally developed based on molecular modeling and/or assumptions about potential 
activities with respect to structure-activity relationships (Figure 1).3 In any case, the ability to 
easily append substituents and position them in three-dimensional space also plays a vital role in 
improving the potency and the selectivity of the binding interaction.4 
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Figure 1. A representation of some of the commonly implemented approaches for the identification of hits/leads. 
 
Regardless of the methodology used to obtain these novel scaffolds, many researchers are 
successful in the synthesis of unique structures that could lead to innovative, biologically active 
compounds. The Centers for Chemical Methodologies and Library Development (CMLD) 
initiative was specifically sponsored by the NIH/NIGMS to identify novel library structures.  
11 
1.1 REQUIREMENTS FOR NOVELTY 
At the structural level, the newly designed novel scaffolds should meet some basic 
benchmarks of druglikeness, such as the Lipinski5 and Veber rules,6 to prove their drug 
development potential. Furthermore, they should not be “frequent hitters” in biological assays or 
demonstrate unusual reactivity or redox properties.7 High quality core structures are readily 
modified by introducing a variety of substituents that can improve pharmacological properties 
such as potency, affinity, and specificity as well as physical properties such as solubility.8  For 
example, studies have shown that halogen substituents on the aromatic moiety of the tetracaine 
scaffold show an enhanced potency at cyclic nucleotide-gated channels in comparison with other 
aromatic substitutions.9  However, enhancing a compound’s binding affinity by adding 
hydrophobic groups might end up decreasing its specificity.10 Furthermore, specificity is a main 
concern and its lack thereof might only become apparent after extensive screening efforts or in 
costly late stage human trials.   
An increasing amount of information is being collected on medicinal chemistry scaffolds 
demonstrating broad and undesirable activities in functionally unrelated assays, a hallmark of 
“frequent hitters”. In 1988, Evans and colleagues introduced the notion of compounds with 
multiple activities, so called “privileged structures”.11 Although this term’s definition was 
generalized by Evans, subsequent studies categorized it and set up the differences between 
privileged and “promiscuous” structures.12,13,14 Experience-based as well as computational 
approaches have been dedicated to discerning the structural differences between privileged and 
promiscuous scaffolds.15,16  “Privileged scaffolds” is a term used to refer to scaffolds that are 
able to bind to multiple targets without losing specificity, i.e. they are frequently found in hit 
molecules in diverse assays but their side chain composition easily allows for the introduction of 
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specificity.14  Promiscuous scaffolds are frequent hitters binding to multiple targets of different 
families without the opportunity to gain significant selectivity or high potency through side chain 
variations. Often, modifying the substituents does not alter the activity substantially, or then, 
quite in the opposite, the activity is completely lost if substituents are varied; i.e. it is not 
uncommon for promiscuous scaffolds to have either unusually “flat” or “steep” SAR trends.17 
To some extent, promiscuity is related to polypharmacology; for instance, some 
pharmacologists postulate that having a drug that would bind and (de)activate targets of different 
families to generate a more complex response pattern would be an advanced and possibly more 
successful approach in drug discovery, especially in cancer therapy.18 On the other hand, 
medicinal chemists might be concerned that using structural features that enable lead compounds 
to interact with targets of different families could complicate optimization, cause 
pharmacokinetic and drug dosing challenges, and lead to systemic side effects due to general 
lack of specificity.19 
For an extended time period, criteria to differentiate between privileged and promiscuous 
scaffolds have been lacking, but a recently formulated rule states that compounds which are 
active against at least three different target families should be considered as promiscuous.20 In 
spite of this criterion, in practice the two concepts are still controversial and passionately 
discussed, such as the relative merits of benzodiazepines and rhodanines (Figure 2), to name a 
specific example for each. 21, 22 
Figure 2. Benzodiazepine and rhodanine scaffolds. 
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The benzodiazepine nucleus was probably the first and the most important example used 
to describe the term “privileged structure”.11,16  Benzodiazepine derivatives are known for their 
wide range of pharmacological properties in clinical conditions such as anxiety disorders, 
ethanol withdrawal, and convulsive disorders.23  Yet, some scientists consider several 
compounds containing this scaffold as non-specific binders. For example, olanzapine, a 
benzodiazepine antipsychotic, has been shown to bind to multiple receptors for serotonin, 
noradrenaline, muscarine, dopamine and histamine. Although all of the endogenous ligands of 
these latter receptors share the basic amine in their pharmacophores, they have major differences 
in their representative scaffolds which make each molecule selective to its receptor.24,25,26 
Therefore, the promiscuous profile of olanzapine would normally be unacceptable; nonetheless, 
the drug is approved for the treatment of schizophrenia due to its high efficacy for this disorder.27 
Aspirin is another example of a successful promiscuous drug that is widely used. In 
contrast, the rhodanine scaffold gained a reputation of having insignificant value in drug 
discovery due to its nonselectivity.28  Conversely, there are some rhodanine-derived drugs for the 
treatment of type II diabetes mellitus and diabetic complications such as epalrestat.22 There are 
many contradictory observations regarding this scaffold but it is still of high interest to medicinal 
chemists and frequently found as a lead structure in biological studies.  
Other, maybe less hotly contested examples of privileged scaffolds (such as 
dihydropyridine and benzenesulfonamide) and promiscuous compounds (such as quinolines and 
hydantoins) are being discussed in the literature without a credible justification or a standard that 
could be applied by others to determine their specificity and relative potential for further clinical 
development. Non-specificity or promiscuity of small molecules could be identified through 
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many approaches such as database mining,20 lipophilicity measurement,29 and match molecule 
pair (MMP) analysis30. 
In order to annotate some of the novel scaffolds prepared at the University of Pittsburgh 
CMLD and compare to other published scaffolds used for biological assays, we have followed a 
comparative analysis approach based on the interrogation of multiple screening targets.31  
In PubChem, biological data are being collected for many novel compound classes and it 
is relatively simple to analyze the data and correlate them to the chemical structures.32  Based 
mostly on in vitro bioassays, these biological data could be helpful in categorizing the behavior 
of compounds having particular scaffolds of interest. These activity profiles are reflected by the 
active hits* which are usually defined as compounds which have an activity in the range of 30 
µM – 1 nM.33 Accordingly, we selected the biological profiles of four compound libraries from 
the UPCMLD (UPCMLD02A, UPCMLD09A, UPCMLD16A, and UPCMLD24A) (Figure 3) 
and another four compound libraries from the literature for comparison. Among the latter, two 
were generally considered as privileged scaffolds (benzodiazepines and dihydropyridines) and 
the remaining two could be claimed as promiscuous (rhodanines and quinolines) (Figure 4).28, 34   
Figure 3. The scaffolds of four UPCMLD libraries. Substructures 1,2,3, and 4 are also referred to as UPCMLD09A, 
UPCMLD02A, UPCMLD16A, and UPCMLD24A, respectively, in the PubChem database. 
*In the PubChem database, some concentration values of hits are not provided.
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Figure 4. The scaffolds of four libraries from the literature. Substructure 5 shows the benzodiazepine nucleus, 6 is a 
dihydropyridine scaffold, 7 shows the quinoline nucleus, and 8 is a rhodanine. Substructures 5 and 6 are generally 
referred to as privileged scaffolds while compounds with substructures 7 and 8 are often considered as promiscuous. 
Our general approach can be summarized as follows: the biological data of both the 
UPCMLD and the literature scaffold libraries were extracted from the PubChem database and 
analyzed.  The biological data of each library contained activity profiles of compounds screened 
in different bioassays. Our effort was to determine if UPCMLD scaffolds would result in 
important screening compounds by benchmarking their libraries against the literature libraries. 
Literature libraries of renowned and emerging scaffolds in drug discovery (Figure 4) were used 
as relative references to assure a plausible analytical approach.  In order to ensure an unbiased 
analysis, an extensive filtering process was followed.   
Beginning with extracting data and excluding unshared bioassays and compounds 
screened in less than 100 bioassays, the eight libraries were analyzed and compared to each 
other. By generating graphs of the activities of individual compounds in relation to the bioassays, 
we managed to identify the promiscuous behavior of some scaffolds and representative 
compounds. This was achieved by creating specificity determinants such as the library hit rate.  
16 
2.0  METHODOLOGY 
2.1 LIBRARY SELECTION 
2.1.1 UPCMLD Libraries 
The biological data of the UPCMLD09A library35 was extracted from PubChem and 
analyzed in November 2012. The library contained 75 novel tricyclic pyrrolidine heterocycles 
(Appendix Table 1).  
UPCMLD02A, a library of tricyclic pyrrole-2-carboxamides36, contained 196 compounds 
(Appendix Table 2). Only 193 compounds were biologically tested (January, 2013).  
The piperazinedione-fused tricyclic scaffold in the UPCMLD16A library37 was contained 
in 62 compounds (Appendix Table 3). However, only 54 of these compounds were tested 
biologically (February, 2013).  
In the UPCMLD24A library, the thiadiazine core was the scaffold of 79 compounds38 
(Appendix Table 4); 71 compounds were tested biologically (February, 2013). 
2.1.2 Literature Libraries 
The benzodiazepine library had only 60 out of 15,583 compounds that were screened in 
≥100 bioassays (March, 2013) (Appendix Table 5).  
The dihydropyridine scaffold library had a comparable number of compounds that were 
tested in ≥100 bioassays, i.e. 261 compounds (April, 2013) (Appendix Table 6).   
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PubChem results of the promiscuous rhodanine scaffold showed a huge number of 
compounds: 162,351 compounds. However, only 1,301 compounds were tested in ≥100 
bioassays (May, 2013). 
The tetrahydro-3H-cyclopentaquinoline library had 81 compounds tested in ≥100 
bioassays in that library (June, 2013) (Appendix Table 8). 
2.2 LIBRARY FILTERING 
We found many duplicated bioassays at different concentrations and many similar 
bioassays shown as separate screens. Therefore, we excluded duplicates and similar bioassays. 
For example, the fluorescence-based (AID†:434989) and the FRET-based (AID:485270) cell-
based primary HTS assay to identify antagonists of the orexin 1 receptor were considered as one 
bioassay.  
Another issue was a significant divergence of the bioassays for different libraries; 
therefore we only considered common bioassays and correspondingly reanalyzed the data to 
facilitate the analysis process. As a result, 223 shared screening and confirmatory assays were 
used for all libraries (Appendix Table 9, Figure 5 and Table 1). Since not all concentration values 
were provided in the PubChem database, we did not include them in the analysis. 
† AID: Pubchem bioassay accession; bioassay identification number. 
 18 
 
Figure 5. A summary of the unfiltered number of compounds in UPCMLD and literature libraries. 
 
Table 1. A summary of the number of compounds in UPCMLD and literature libraries before and after filtering.  
Compound Library Number of Compounds 
Before Filtering 
Number of Compounds 
After Filtering 
UPCMLD09A 75 64 
UPCMLD02A 193 28 
UPCMLD16A 62 53 
UPCMLD24A 71 71 
Benzodiazepines 60 54 
19 
Dihydropyridines 261 249 
Rhodanines 85 81 
Quinolines 81 72 
Furthermore, we excluded all library compounds that were screened in less than 100 
bioassays. Due to the large number of compounds in some literature libraries, we decided not to 
exceed 2,000 compounds for each library to allow relevant comparison with UPCMLD libraries. 
Although the number of compounds in the rhodanine scaffold library did not exceed 2,000, we 
followed this criterion initially by filtering out substituents at the N-atom. As a result, only 85 
compounds tested in ≥100 bioassays were used (Appendix Table 7).  
2.3 SOFTWARE USED 
Chemical and biological data were obtained from the PubChem database in spreadsheets. 
Literature libraries were obtained by using the substructure search in PubChem software. 
Both the IBM SPSS 20 program and Microsoft Office Excel 2007 were utilized for data 
analysis and the generation of graphs.  
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2.4 SPECIFICITY DETERMINANTS 
The hit rate was used to reflect the libraries’ activity profiles. It was calculated using the 
following equation:  
𝐻𝑖𝑡  𝑅𝑎𝑡𝑒  𝑜𝑓  𝑎  𝐿𝑖𝑏𝑟𝑎𝑟𝑦 =    𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑎𝑐𝑡𝑖𝑣𝑒  𝑐𝑜𝑚𝑝𝑢𝑛𝑑𝑠  𝑡𝑜𝑡𝑎𝑙  𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑𝑠   ∗ 100% 
The number of active hits for each compound was also utilized to reflect specificity of 
binding.  
The statistical parameters, mean and standard deviation, were used to facilitate 
interpretation in estimating the activity variability of libraries as well as properties. The mean 
indicates the average number of positive hits for compounds while the standard deviation 
corresponds to the variance of compounds’ activity in a library.  
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3.0  RESULTS AND DISSCUSION 
In our attempt to analyze the biological behavior of compounds of some scaffold 
libraries, we used an approach that facilitated data analysis and interpretation. 
Libraries, UPCMLD09A, UPCMLD02A, UPCMLD16A, and UPCMLD24A were 
selected due to the considerable number of compounds and various bioassays they contained, 
since the other UPCMLD libraries had either few compounds or their compounds were not 
screened in a comparable number of bioassays; i.e. 100 bioassays or more.  
After filtering the UPCMLD09A library, 64 compounds out of 75 were left. It was shown 
that these 64 compounds have a low number of hits individually, with 4 bioassays as the 
maximum number of hits (Figure 6 A and B). The UPCMLD09A library showed a relatively 
high hit rate, 51.6%. Since duplicate bioassays became an issue that inflated the number of total 
bioassays and eventually altered the hit rate and other determinants, Figure 6C was generated to 
ensure that these bioassays were excluded and the input data met the criterion discussed 
previously; i.e. only 223 shared bioassays were used.  
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Figure 6.  Graphs summarizing the bioactivity of UPCMLD09A compounds. Graph A shows the number 
of compounds versus the number of active bioassays indicating how many compounds are active in these bioassays 
(hit rate: 51.6%). Graph B shows the number of active bioassays for individual compounds in the UPCMLD09A 
library. CID, the PubChem compound identifier, is a unique identifier given to each chemical structure in the 
PubChem database. Graph C shows that compounds tested in <100 bioassays were filtered out and that only the 
shared 223 bioassays were included in the analysis. 
 
As stated previously, UPCMLD02A is the largest among the UPCMLD libraries and 
contains 196 compounds. However, an unexpected decrease in the number of its compounds 
after filtering was apparent. As shown in Figure 7, the number of compounds was decreased to 
only 28 samples. Some of these compounds were shown to interact with a considerable number 
of targets; CID:3247230 had 36 hits and CID:3247132 provided 12 hits (Appendix Figure 1A). 
A modest hit rate (39.3%) and some promiscuity was observed in the UPCMLD02A library.  
C 
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Figure 7.  A graph representing the number of compounds in the UPCMLD02A library versus the number 
of active bioassays indicating the number of compounds that are found as active hits in different bioassays (hit rate: 
39.3%).  
 
UPCMLD16A showed somewhat better results than UPCMLD02A. 53 Compounds were 
included for analysis and a low number of active bioassays for individual compounds with a 
maximum of 3 hits was found (Figure 8). However, the majority of the compounds had no 
activity in any of the bioassays. Accordingly, this resulted in a relatively low hit rate; 30.2% 
(Appendix Figure 2A).   
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Figure 8.  A graph representing the number of compounds in the UPCMLD16A library that are found as 
active hits in different bioassays (hit rate: 30.2%).  
 
UPCMLD24A was the limiting library in this study since it has been less biologically 
explored. None of its compounds were excluded, making it the largest UPCMLD library with the 
greatest number of compounds after filtering (Figure 9). However, most of these compounds did 
not show any activity in any bioassay; this led to a comparatively low hit rate (25.4%). No more 
than 5 active hits for individual compounds were found (Appendix Figure 3A). 
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Figure 9.  A graph representing the number of compounds in the UPCMLD24A library that are found as active hits 
in different bioassays (hit rate: 25.4%). 
 
The results for the benzodiazepine and dihydropyridine libraries were anticipated due to 
their reputation as privileged scaffolds. The 54 benzodiazepines showed collectively a low 
number of hits (Appendix Figure 4A) and a hit rate of 35.2% (Figure 10). The dihydropyridine 
scaffold library contained 249 compounds after filtering and showed a positively skewed 
bioactivity profile with a 53.0% hit rate (Figure 11). Some dihydropyridines also showed a 
relatively high number of hits (Appendix Figure 5A); for example, CID: 4499 was found active 
in 10 bioassays.  
In comparing UPCMLD libraries to these privileged literature scaffolds, it was observed 
that the results for the UPCMLD libraries were quite similar to the privileged compounds. 
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However, the UPCMLD02A library had two compounds that were exceeding the maximum 
number of active bioassays (10 in the dihydropyridine scaffold library) among all other libraries. 
Accordingly, the UPCMLD02A tricyclic pyrrole-2-carboxamides are suspected to have at least 
in part a promiscuous character. Another reason that led us to the latter conclusion is that only 28 
compounds were tested on the shared 223 bioassays. Nonetheless, the nature of the bioassays 
was not explored in detail, and some compounds might be active in bioassays that are refering to 
multiple targets of the same family. Therefore, we analyzed the bioassays with positive results 
for the two UPCMLD02A compounds and found that the majority were refering to different 
families (Figure 12). 
 
 
 Figure 10.  A graph representing the number of compounds with the benzodiazepine scaffold that are found as 
active hits in different bioassays (hit rate: 35.2%). 
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Figure 11.  A graph representing the number of compounds with the dihydropyridine scaffold that are found as 
active hits in different bioassays (hit rate: 53.0%). 
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 Figure 12.  A representation of some of the active bioassays  for two UPCMLD02A frequent hitters (not all active 
bioassays are shown for clarity purposes). 
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To avoid any bias, we compared the UPCMLD libraries to the promiscuous literature 
scaffold libraries. Rhodanine (Figure 13 and Appendix Figure 6) and quinoline (Figure 14 and 
Appendix Figure 7) scaffold libraries showed a high level of promiscuity. Although their hit 
rates were much higher than those of the UPCMLD libraries (86.4% for rhodanines and 80.6% 
for quinolines), these high numbers have little value when the cost is a loss of specificity. In 
addition, standard deviation values of rhodanine and quinoline scaffold libraries were 
considerably higher than UPCMLD09A, UPCMLD16A, and UPCMLD24A, indicating a broad 
variability in the bioactivity of compounds in former libraries. Owing to the high variability, the 
mean became an unreliable method to indicate the average number of active hits in the two 
promiscuous scaffold libraries. 
Although the rhodanine scaffold library was initially filtered due to the large number of 
compounds i.e. 1,301 compounds, we did not alter the filtering process since we were expecting 
a promiscuous profile, and the results were as anticipated.  
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Figure 13.  A graph representing the number of compounds with the rhodanine scaffold that are found as active hits 
in different bioassays (hit rate: 86.4%). 
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Figure 14.  A graph representing the number of compounds with the quinoline scaffold that are found as active hits 
in different bioassays (hit rate: 80.6%). 
 
In summary, we have implemented a comparative approach to determine the nature  of 
the novel UPCMLD scaffold libraries as it pertains to promiscuity and/or privileged character. 
UPCMLD09A showed relatively high selectivity, taking into account the number of compounds 
involved, the library hit rate, and the low number of actives in bioassays (Table 2). Therefore, the 
UPCMLD09A scaffold might provide high quality screening samples. The UPCMLD02A library 
showed a tendency for promiscuity, although only 28 compounds were included in the 
comparison, due to bioassay limitations.  
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Table 2. A summary of the results of UPCMLD and literature scaffold libraries.  
Compound 
Library 
Library Hit Rate 
Maximum 
Number of Hits 
for Individual 
Compounds 
Mean of  Hits for 
Individual 
Compounds 
Standard 
Deviation of Hits 
for Individual 
Compounds 
UPCMLD09A 51.6% 4 1 1 
UPCMLD02A 39.3% 36 2 7 
UPCMLD16A 30.2% 3 0 1 
UPCMLD24A 25.4% 5 0 1 
Benzodiazepines 35.2% 5 1 1 
Dihydropyridines 53.0% 10 1 1 
Rhodanines 86.4% 42 6 7 
Quinolines 80.6% 33 7 8 
 
By comparing the UPCMLD libraries with compound libraries from the literature, we 
learned that the novel UPCMLD scaffolds can provide high quality screening samples. However, 
testing the quality of novel scaffolds could be carried out considering other structural aspects, 
such as comparison of functionalities, rigidity, and lipophilic character.  
In addition, the selection of bioassays in this research was limited since the UPCMLD 
libraries were less biologically explored than the literature scaffold libraries. Therefore, the 
selected bioassays might not be conclusive to reflect the actual nature of the libraries.  
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Furthermore, we disregarded concentration values of active hits bacause not all values 
were provided in the PubChem database. This is a potentially significant limitation due to the  
importance of concentration values in binding specificity. 
Another important aspect that might be a caveat in this study is the number of compounds 
representing a specific scaffold in a library. In UPCMLD02A for example, 28 compounds are too 
few to adequately assess the quality of the tricyclic pyrrole-2-carboxamide core structure.  
Finally, based on the currently available information about privileged and promiscuous 
scaffolds and our knowledge regarding promiscuity, the quality of novel scaffolds could be 
identified by several different processes. Therefore, our approach is not a universal approach to 
identify quality in new scaffolds, but it certainly provides an important benchmark that reflects 
the biological response to structural features of organic molecules. 
 
 
 
 
 
35 
APPENDIX A 
SUPPLEMENTARY DATA 
Appendix Table 1. A list of the compounds in the UPCMLD09A library 
CID R1 R2 R3 R4 
11949236 
11949235 
11949234 
 36 
11949233 
 
 
  
11949232 
 
 
  
11949231   
  
11949230 
  
 
 
11949229 
  
 
 
11949228 
 
 
 
 
11949227 
 
 
  
 37 
11949226   
 
 
11949225 
  
 
 
11949224 
  
 
 
11949223 
 
 
 
 
11949222 
 
 
 
 
11949221   
 
 
11949220 
    
11949219 
    
 38 
11949218 
 
   
11949217 
 
   
11949216     
11949215 
   
 
11949214 
   
 
11949213 
 
  
 
11949212 
 
  
 
 39 
11949211    
 
11949210 
    
11949209 
 
  
 
11949208 
 
  
 
11949207    
 
11949206 
   
 
11949205 
   
 
11949204 
 
  
 
 40 
11949203 
 
  
 
11949202    
 
11949201 
    
11949200 
    
11949199 
 
   
11949198 
 
   
11949197     
11949196 
    
11949195 
    
 41 
11949194 
 
   
11949193 
 
   
11949192     
11949191 
  
 
 
11949190 
  
 
 
11949189 
 
 
 
 
11949188 
 
 
 
 
 42 
11949187   
 
 
11949186 
  
  
11949185 
  
  
11949184 
 
 
  
11949183 
 
 
  
11949182   
  
11949181 
  
 
 
 43 
11949180 
  
 
 
11949179 
 
 
 
 
11949178 
 
 
 
 
11949177   
 
 
11949176 
    
11949175 
    
11949174 
 
  
 
11949173 
 
  
 
 44 
11949172    
 
11949171 
   
 
11949170 
   
 
11949169 
 
  
 
11949168 
 
  
 
11949167    
 
11949166 
    
11949165 
    
 45 
 
11949164 
 
   
11949163 
 
   
11949162     
 
Appendix Table 2a. A list of compounds for the primary scaffold in the UPCMLD02A library 
 
CID R1 R2 R3 
3247074 
 
  
3247075 
 
  
3247076 
   
 46 
3247077 
 
  
3247078 
 
  
3247079 
 
  
3247080 
 
  
3247081 
 
  
3247082 
 
  
3247083 
 
  
 47 
3247084 
 
  
3247085 
 
  
3247086 
 
  
3247087 
 
  
3247088 
 
  
3247089 
 
  
3247090 
 
  
 48 
3247091 
 
  
3247092 
 
  
3247093 
 
  
3247094 
 
  
3247095 
 
  
3247096 
 
  
 49 
3247097 
 
  
3247098 
 
  
3247099 
 
  
3247100 
 
  
3247101 
 
  
3247102 
 
  
 50 
3247103 
 
 
  
3247104 
 
  
3247105 
 
  
3247106 
 
  
3247107 
 
  
3247108 
 
  
 51 
3247109 
 
  
3247110 
 
  
3247111 
 
  
3247112 
 
  
3247113 
 
  
3247114 
 
  
 52 
3247115 
 
  
3247116 
 
  
3247117 
 
 
 
3247118 
 
 
 
3247119 
 
 
 
3247120 
 
 
 
 53 
3247121 
 
 
 
 
3247122 
  
 
 
3247123 
 
 
 
3247124 
 
 
 
3247125 
 
 
 
 54 
3247126 
 
 
 
3247127 
 
 
 
3247128 
 
 
 
3247129 
 
 
 
3247130 
 
 
 
3247131 
 
  
 55 
3247134 
 
  
3247136 
 
  
3247138 
 
  
3247139 
 
  
3247140 
 
  
3247141 
 
  
3247142 
 
  
 56 
3247144 
 
  
3247145 
 
 
  
3247146 
 
  
3247147 
 
  
3247148 
 
  
3247149 
 
  
 57 
3247150 
 
  
3247151 
 
  
3247152 
 
  
3247153 
 
  
3247159 
 
  
 
3247160 
  
  
3247161 
 
  
 58 
3247162 
 
  
3247163    
3247164 
 
  
3247165 
 
  
3247166 
 
  
3247168 
 
 
 
3247169 
 
 
 
 59 
3247170 
 
 
 
3247171 
 
 
 
3247172 
 
 
 
3247173 
 
 
 
3247174 
 
 
 
3247175 
 
 
 
 60 
3247176 
 
 
 
3247177 
 
 
 
3247178 
 
 
 
3247179 
 
 
 
3247180 
  
 
3247181 
 
 
 
 61 
3247182 
 
 
 
3247183 
 
 
 
3247184 
 
 
 
3247185 
   
3247186 
 
  
3247187 
 
  
3247188 
 
  
 62 
3247189 
 
  
3247190 
 
  
3247191 
 
  
3247192 
 
  
3247193 H 
  
3247194 H 
  
3247195 
  
 
3247196 
  
 
 63 
3247197 
 
  
3247198 
 
  
3247199 
 
  
3247200 
 
  
3247201 
 
  
3247202  
  
3247203 
 
  
 64 
3247204 
 
  
3247205 
   
3247206 
   
3247207 
 
  
3247208 
 
  
3247209 
 
  
3247210 H 
  
3247211 H 
  
 65 
3247212 
 
  
3247213 
 
  
3247214 
 
  
3247215 
 
  
3247216 
 
  
3247217 
 
  
3247218 
 
  
3247219    
 66 
3247220 
 
  
3247221 
 
  
3247222 
 
  
3247223 
 
  
3247224 
 
  
3247225 
 
  
3247226 
   
 67 
3247227 
 
  
3247228 
 
  
3247231 
 
  
3247232 
 
  
3247233 
 
 
 
3247234 
 
 
 
 68 
3247235 
 
 
 
3247236 
 
 
 
3247237  
 
 
3247238 
  
 
3247239 
 
 
 
3247240 
 
 
 
 69 
3247241 
 
 
 
3247242 
 
 
 
3247243 
 
 
 
3247244 
 
 
 
3247245 
 
 
 
3247246 
 
 
 
3247247 
  
 
 70 
3247248 
 
 
 
3247249 
  
 
3247250 
 
 
 
3247251 
 
 
 
3247252 
  
 
3247253 
 
 
 
 71 
3247254 H 
 
 
3247255 
 
 
 
3247256 
 
 
 
3247257 
 
 
 
3247258 
 
 
 
3247259 
 
 
 
3247260   
 
 72 
3247261 
 
 
 
3247262 
 
 
 
3247263 
 
 
 
11949594 
 
 
 
50919303 
 
 
 
15965408 
 
 
 
 73 
15965404 
 
 
 
11972257 
 
  
 
 
Appendix Table 2b. A list of compounds for a secondary scaffold in the UPCMLD02A library 
 
CID R1 R2 
3247132 
  
3247133 
  
3247143 
  
 74 
3247156 
 
 
3247158 
 
 
 
 
Appendix Table 2b. A list of compounds for a secondary scaffold in the UPCMLD02A library 
 
CID R1 R2 
3247135 
  
3247154 
  
3247155 
  
3247157± 
 
 
 75 
3247167 
 
 
50919302± 
 
 
 
 
Appendix Table 2d. A list of compounds for a secondary scaffold in the UPCMLD02A library 
 
CID R1 
3247229 
 
3247230 
 
 
 
Appendix Table 2e. A list of a secondary scaffold in the UPCMLD02A library 
 
 76 
CID R1 
50919301 
 
 
 
 
Appendix Table 3. A list of the compounds in the UPCMLD16A library 
 
CID R1 R2 R3 R4 
23731318 
   
 
23731357 
 
 
 
 
23731356 
 
 
 
 
 77 
23731355 
 
 
 
 
23731354 
 
 
  
23731353 
 
 
  
23731352 
 
 
 
 
23731351 
 
 
 
 
23731350 
 
 
 
 
23731349 
 
 
 
 
23731348 
 
 
 
 
 78 
23731347 
 
 
 
 
23731346 
 
 
 
 
23731345 
 
 
 
 
23731344 
 
 
 
 
23731343 
 
 
 
 
23731342 
 
 
 
 
23731341 
 
 
 
 
23731340 
 
 
 
 
 79 
23731339 
 
 
 
 
23731338 
 
 
 
 
23731337 
 
 
 
 
23731336 
 
 
  
23731335 
 
 
  
23731334 
 
 
  
23731333 
 
 
  
23731332 
 
 
  
 80 
23731331 
 
 
  
23731330 
 
 
  
23731329 
 
 
  
23731328 
 
 
 
 
23731327 
 
 
 
 
23731326 
   
 
23731325 
 
  
 
23731324 
   
 
 81 
23731323 
 
  
 
23731322 
    
23731321 
   
 
23731320 
   
 
23731319 
   
 
23731317 
   
 
23731316 
    
23731315 
 
 
 
 
23731314 
   
 
 82 
23731313 
   
 
23731312 
   
 
23731311 
    
23731310 
   
 
23731309 
 
 
 
 
23731308 
   
 
23731307 
   
 
23731306 
    
23731305 
    
 83 
23731304 
    
23731303 
    
23731302 
   
 
23731301 
   
 
23731300 
   
 
23731299 
 
  
 
23731298 
   
 
23731297 
   
 
 84 
23731296 
    
 
 
Appendix Table 4a. A list of compounds for the primary scaffold in the UPCMLD24A library 
 
CID R1 R2 R3 R4 R5 
42628032 H H 
 
 
H 
42628031 H H 
  
H 
42628030 H H 
  
H 
42628029 H H 
 
 
H 
42628028 
 
H 
  
 
42628027 
 
H 
 
 
 
 85 
42628026 
 
H 
  
 
42628025 
 
H 
 
  
42628024 
 
H  
 
  
42628023 
 
H 
  
 
42628022 
 
H 
 
 
 
42628021 
  
H 
  
 
42628020 
  
H 
 
  
42628019 
 
H 
  
 
42628018 
 
H 
  
 
42628017 
 
H 
  
 
 86 
42628016 
 
H 
   
42628015 
 
H 
 
 
 
42628014 
 
H 
  
 
42628013 
 
H 
  
 
42628012 
 
H 
  
 
42628011 
 
H 
  
 
42628010 
 
H 
 
 
 
42628009 
 
H 
  
 
42628008  H 
  
H 
42628007  H 
  
H 
 87 
42628006  H 
 
 
H 
42628005  H 
  
H 
42628004  H 
 
 H 
42628003  H 
  
H 
42628002  H 
  
H 
42628001 
 
H 
  
H 
42628000 
 
H 
  
H 
42627999 
 
H 
 
 
H 
42627998 
 
H 
  
H 
42627997 
 
H 
 
 H 
 88 
42627996 
 
H 
  
H 
42627995 
 
H 
  
H 
42627994 
 
H 
  
H 
42627993 
 
H 
  
H 
42627992 
 
H 
   
42627991 
 
H 
  
 
42627990 
 
H 
  
H 
42627989 H H 
  
H 
42627988 H H 
  
H 
42627987 
 
H 
   
42627986 
 
H 
  
H 
 89 
42627985 H H 
  
H 
42627984 
 
H 
  
 
42627983 H H 
  
H 
42627982 
 
H 
  
 
42627981 
 
H 
 
  
42627980 
 
H 
 
  
42627979 
 
H 
 
 H 
42627978 
 
H 
 
 H 
42627977 
 
H 
 
  
42627976 
 
H 
 
  
 90 
42627975 
 
H 
 
  
42627974 
 
H 
 
  
42627973 
 
H 
 
  
42627972 
 
H 
 
  
42627971 
 
H 
 
  
42627970 
 
H 
 
 H 
42627969 
 
H 
 
 
 
42627968 
 
H 
 
  
42627967 
 
H 
 
 
 
42627966 
 
H 
 
  
42627965 
 
H 
 
 H 
 91 
42627964 
 
 
 
H 
 
42627963 H  
 
H 
 
42627962 
 
 
 
H 
 
42627961 H  
 
H 
 
42627960 H H 
  
H 
42627959 H H 
  
H 
42627958 H H 
  
H 
 
 
CID R1 R2 R3 R4 R5 
42628033 
 
H H 
 
 
H 
 
 
 92 
Appendix Table 4b. A list of compounds for a secondary scaffold in the UPCMLD24A library 
 
CID R1 R2 
18526094 
 
 
12196531 
 
 
12196529 
 
 
 
 
Appendix Table 5a. A list of compounds for the primary scaffold in the benzodiazepines library that was screened 
in ≥100 bioassays 
 
CID R1 R2 R3 R4 
3016  H 
 
Cl 
 93 
1688  H 
 
Cl 
3239992 
 
H 
 
H 
3242322 
 
H 
 
Cl 
3241670 
 
H 
 
H 
661451 H 
  
H 
292106 
 
H 
 
Cl 
4067095 
 
H 
 
Cl 
3769982 H 
 
 
Br 
 94 
627336 H 
  
Br 
4540 H H 
 
Cl 
3763028 H 
  
 
4227629 
 
H 
 
Cl 
9550458 
 
 
 
Cl 
3812960 
 
H 
 
H 
629081  
  
Br 
3780845 
 
H 
 
H 
 95 
3782732 
 
H 
 
H 
4053467 
 
H 
 
H 
3645286 
 
H 
 
Br 
15945564 
 
H 
 
H 
125820 H OH 
 
Br 
15945507 
 
 
 
Cl 
2912834 H 
  
Br 
15992383 
 
H 
 
H 
 96 
16188013 H 
 
 
Br 
627086 
 
H 
 
Br 
4506 H H 
  
64983 H H 
 
Cl 
4227633 
 
H 
 
H 
4231220 
 
H 
 
H 
4231219 
 
H 
 
H 
 97 
121919 
 
H 
 
Br 
631729  
  
Br 
630731 H 
  
Br 
1985588 
 
H 
 
Br 
76175 H H 
 
H 
76167 H H 
 
Br 
625577 H  
 
Br 
613848 H H 
 
 
781348 H H 
 
Br 
 98 
3525607 
 
 
 
Cl 
632515  H 
 
Br 
614001 H OH 
 
H 
627325 H OH 
 
Br 
633837 H H 
 
Br 
629437 H  
 
Br 
617083  OH 
 
H 
3676999 H OH 
 
Br 
4496  H 
  
 99 
2835734 H H 
  
1108855  H 
 
 
40113 H H 
 
Br 
3958 H OH 
 
Cl 
2802 H H 
  
4616 H OH 
 
Cl 
457993  H 
 
Cl 
443375  
  
H 
5391  OH 
 
Cl 
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Appendix Table 5b. A list of a secondary scaffold in the benzodiazepines library that was screened in ≥100 
bioassays 
 
CID R1 R2 R3 R4 
72793  H 
 
Cl 
 
 
 
Appendix Table 6a. A list of compounds for the primary scaffold in the dihydropyridines library that was screened 
in ≥100 bioassays 
 
CID R1 R2 R3 R4 R5 
4485    
 
 
3333    
 
 
 101 
4507±    
 
 
4497    
 
 
2998930    
 
 
2998073    
 
 
70849    H  
99955    
 
 
645054    
 
 
356261    
 
 
 102 
674174 H H  
 
 
614258    
 
 
2997634    
 
 
3000076    
 
 
715615 H H  
 
 
2998190    
 
 
 103 
2998245    
 
 
654190    
 
 
653396    
 
 
2998525    
 
 
2998988    
 
 
646414    
 
 
 104 
652775    
 
 
646662    
 
 
41114±    
 
 
97201    
 
 
1179153    
 
 
2873602    
 
 
619963    
 
 
 105 
2874327    
 
 
607320 H H  
 
 
830797      
168683      
2999719    
 
 
299857 H H  
 
 
101991    
 
 
980133    
 
 
89082    
 
 
 106 
980118    
 
 
4372140    
 
 
2162± 
 
  
 
 
3552238    
 
 
741918    
 
 
2891841    
 
 
5036384    
 
 
 107 
1481403    
 
 
741915    
 
 
5349621    
 
 
12446      
4542777    
 
 
2891805    
 
 
1116476      
979574    
 
 
979103    
 
 
 108 
3713405    
 
 
4499    
 
 
 
3139744 
 
   
 
 
3784    
 
 
1521795    
 
 
211447    
 
 
 
1523976 
 
   
 
 
 109 
4225909    
 
 
4640338    
 
 
4876664    
 
 
3655532    
 
 
1330517    
 
 
3527455    
 
 
 110 
4882233    
 
 
3278447    
 
 
5457261    
 
 
15944995    
 
 
4291090    
 
 
 111 
4037186    
 
 
5040203    
 
 
4833026    
 
 
211446    
 
 
330513    
 
 
2891790    
 
 
2891717    
 
 
2832255    
 
 
 112 
1042586    
 
 
5788116    
 
 
206197    
 
 
680018    
 
 
4874926    
 
 
979325    
 
 
2729685    
 
 
698276    
 
 
 113 
60496± 
 
  
 
 
607376 H H  
 
 
3290996    
 
 
 
 
 
4597530    
 
 
24980278    
 
 
1355281    
 
 
 114 
16235098    
 
 
16269372    
 
 
16303100    
 
 
656667    
 
 
5178648    
 
 
 115 
4377834    
 
 
4877032    
 
 
16251224    
 
 
3952096    
 
 
5206524    
 
 
 116 
3952099    
 
 
3952101    
 
 
4010124    
 
 
4350308    
 
 
5311217    
 
 
 117 
4003931    
 
 
4527347    
 
 
16331146    
 
 
4878417    
 
 
4474±    
 
 
 118 
3924081    
 
 
282663    
 
 
323302    
 
 
3578429    
 
 
3954720    
 
 
322224    
 
 
 119 
60602    
 
 
157704±    
 
 
124236     
 
5282138    
 
 
158617    
 
 
157132    
 
 
 
 120 
 
Appendix Table 6b. A list of compounds for a secondary scaffold in the dihydropyridines library that was screened 
in ≥100 bioassays 
 
CID R1 R2 R3 R4 R5 R6 
2172352 H 
 
H  
 
 
647803 H  H  
 
 
2171942 H 
 
H  
 
 
758229     
 
 
1515332 H 
 
H  
 
 
 121 
1313404 H 
 
H  
 
 
742390     
 
 
2265768     
 
 
40672     
 
 
649789 H  H  
 
 
2221501 H 
 
H  
 
 
2055736 H 
 
H  
 
 
2172338 H 
 
H  
 
 
 122 
1368638     
 
 
2172337 H 
 
H  
 
 
610962 H  H  
 
 
743917     
 
 
2906112 H 
 
H  
 
 
616915 H 
 
H  
 
 
646475 H  H  
 
 
653593 H 
 
H  
 
 
621599     
 
 
 123 
674186     
 
 
714587     
 
 
2052813 H 
 
H  
 
 
614266 H 
 
H  
 
 
1336353 H  H  
 
 
1087398     
 
 
617111     
 
 
2291187 H 
 
H  
 
 
 124 
775764 H 
 
H  
 
 
616871 H 
 
H  
 
 
644677 H 
 
H  
 
 
2195084 H 
 
H  
 
 
2936404 H 
 
H  
 
 
1043709     
 
 
625873     
 
 
2168053 H 
 
H  
 
 
 125 
623049     
 
 
1294819 H 
 
H  
 
 
2052819 H 
 
H  
 
 
2233519 H 
 
H  
 
 
1043689 H 
 
H  
 
 
3684684 H 
 
H  
 
 
2936351 H 
 
H  
 
 
325406     
 
 
 126 
1297295 H 
 
H  
 
 
1073334 H 
 
H  
 
 
2169339 H 
 
H  
 
 
2172353 H 
 
H  
 
 
2976701 H 
 
H  
 
 
1073346 H 
 
H  
 
 
2052604 H 
 
H  
 
 
1073796 H 
 
H  
 
 
 127 
1094573 H 
 
H  
 
 
623928     
 
 
5131501 H 
 
H  
 
 
1158246 H 
 
H  
 
 
2233288 H 
 
H  
 
 
1336608 H 
 
H  
 
 
2194667 H 
 
H  
 
 
2917066 H 
 
H  
 
 
1547954  
 
  
 
 
 128 
1272579 H 
 
H  
 
 
1357611  
 
  
 
 
11538542  
 
  
 
 
1073338 H 
 
H  
 
 
1294867 H 
 
H  
 
 
 
1073328 H 
 
H  
 
 
3692778 H 
 
H  
 
 
 129 
1298163 H 
 
H  
 
 
1336676 H 
 
H  
 
 
1050959 H 
 
H  
 
 
1094423 H 
 
H  
 
 
1201780 H 
 
H  
 
 
3158412 H 
 
H  
 
 
1313969 H 
 
H  
 
 
2897978 H 
 
H  
 
 
 130 
1094429 H 
 
H  
 
 
1261225 H 
 
H  
 
 
1322301 H 
 
H  
 
 
1094572 H 
 
H  
 
 
2898344 H 
 
H  
 
 
1094619 H 
 
H  
 
 
1262626 H 
 
H  
 
 
 131 
1202534 H 
 
H  
 
 
1262617 H 
 
H  
 
 
1073349 H 
 
H  
 
 
1295422 H 
 
H  
 
 
1531944 H 
 
H  
 
 
1094686 H 
 
H  
 
 
1295694 H 
 
H  
 
 
 132 
1295301 H 
 
H  
 
 
1298115 H 
 
H  
 
 
1349549 H 
 
H  
 
 
1296864 H 
 
H  
 
 
1094770 H 
 
H  
 
 
1094685 H 
 
H  
 
 
1296921 H 
 
H  
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Appendix Table 6c. A list of compounds for a secondary scaffold in the dihydropyridines library that was screened 
in ≥100 bioassays 
CID R1 R2 R3 R4 R5
1519307 
226671 
629929 
1547825 
714649 
2229373 
 134 
632200    
 
 
1511235    
 
 
323487    
 
 
684250    
 
 
2739835    
 
 
2739782    
 
 
282662    
 
 
 
 135 
Appendix Table 6d. A list of compounds for a secondary scaffold in the dihydropyridines library that was screened 
in ≥100 bioassays 
 
CID R1 R2 R3 
721596    
1508705    
 
 
 
Appendix Table 6d. A list of a secondary scaffold in the dihydropyridines library that was screened in ≥100 
bioassays 
 
CID R1 R2 R3 
766691    
 
 136 
 
Appendix Table 6e. A list of a secondary scaffold in the dihydropyridines library that was screened in ≥100 
bioassays 
 
CID R1 R2 R3 
4621225   
 
 
 
 
Appendix Table 6f. A list of compounds for a secondary scaffold in the dihydropyridines library that was screened 
in ≥100 bioassays 
 
CID R1 R2 R3 R4 
5863694 
 
 
 
 
16410242 
 
 
 
 
 137 
2968682   
 
 
2966579   
 
 
660793 H  H  
5940036 
 
 
 
 
5917962 
 
  
 
5789170 
 
 
 
 
751468 H 
 
H 
 
4587577   
 
 
5761865 
 
 
 
 
 138 
5929786 
 
 
 
 
5929103 
 
 
 
 
5189086   
 
 
3487882   
 
 
2969954   
 
 
5939372 
 
 
 
 
5702971 
 
 
 
 
5783507 
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Appendix Table 7. A list of the compounds in the rhodanine scaffold library that was screened in ≥100 bioassays 
 
CID R 
12004907 
 
12005023 
 
1201546 H 
1201959 
 
1205767 
 
1206896 
 
 140 
1235243 
 
1236046 
 
1236050 
 
1237580 
 
1241127 
 
1273210 
 
1309706 
 
1329072 
 
1331044 
 
 141 
1350270 
 
1367790 
 
1370241 
 
1370249 
 
1381466 
 
1385343 
 
 142 
1388377 
 
1420281 
 
1613528 
 
16195300 
 
1624667 
 
1742917 
 
 143 
1849004 
 
1855553 
 
1863779 
 
1922475 
 
1960206 
 
1962679 
 
 144 
2000865 
 
2030134 
 
2163119 
 
2175545 
 
2268032 
 
 145 
2272421 
 
2272534 
 
2387166 
 
2723826 
 
2785114 
 
2787034 
 
2787053 
 
2796945 
 
 146 
2796946 
 
2796949 
 
2826383 
 
2826563 
 
2830585 
 
2844976 
 
2848355 
 
2859659 
 
2864576 
 
 147 
3004477 
 
3034543 
 
3034572 
 
3095430 
 
4302151 
 
5042127 
 
5151023 
 
5178496 
 
5292926 
 
 148 
5293996 
 
5335985 
 
5585899 
 
5712384 
 
5751473 
 
5756549 
 
5756550 
 
5757257 
 
 149 
5767616 
 
5913361 
 
5953071 
 
6007691 
 
6243032 
 
6300280 
 
6398921 
 
6532825 
 
659551 
 
664780 
 
 150 
7101311 
 
7185334 
 
9551861 
 
 
 
 
Appendix Table 8a. A list of compounds for the primary scaffold in the quinolines library that was screened in 
≥100 bioassays 
 
CID R1 R2 R3 R4 
1203912 
 
H 
 
H 
 151 
15945793 
 
Cl 
 
H 
16738614 
 
H  H 
16738622 
 
H  H 
16738628 
 
F  H 
16738630 
 
H 
 
H 
16738632 
 
H 
 
H 
16738633 
 
H 
 
H 
16738634 
 
H 
 
H 
16738635 
 
H 
 
H 
16738636 
 
H 
 
H 
 152 
16738638 
 
H 
 
H 
16738640 
 
H 
 
H 
16738641 
 
H 
 
H 
16738647 
 
H 
 
H 
16738649 
 
H 
 
H 
16738651 
 
H 
 
H 
16738654 
 
H 
 
H 
16738663 
 
H H H 
16738667 
 
H H H 
2839743  H 
 
H 
2859888 
 
H 
 
H 
 153 
2865731 
 
Cl Cl H 
2872045 
  
H H 
2873402 H  
 
H 
2874547 
 
H 
 
H 
2874832 
 
H 
 
H 
2947620 
 
H 
 
H 
2975102 
 
Cl Cl Cl 
2975117 
 
H Br H 
2975144 
 
H 
 
H 
2975162 
 
  H 
 154 
2978460 
 
H 
 
H 
2980797 
 
Cl H 
 
2982494 
 
Cl H 
 
2984654 
 
F H H 
3136296 
 
H 
 
H 
3136298 
 
H 
 
H 
3136304 
 
H 
 
H 
3136748 
 
H 
 
H 
3136783 
 
H F H 
3136844 
 
H H H 
 155 
3136846 
 
H  H 
3136849 
 
H 
 
H 
3136927 
 
H Br H 
3136931 
 
H 
 
H 
3145169 
 
H 
 
H 
3154276 
 
H 
 
H 
3154395 
 
Cl H 
 
3154407 
 
Cl H 
 
3154424 
  
  
3154430 
 
 
 
H 
3243550 
 
H 
 
H 
 156 
3406013 
 
OH Cl 
 
3437213 
 
F Br H 
3453217 
 
OH Cl 
 
3797563 
 
H 
 
H 
3845516 
  
H Cl 
3850620 
 
H 
 
H 
5322407 
 
H 
 
H 
617227 
  
H H 
619328 
 
H 
 
H 
620366 
 
H 
 
H 
646096 
 
H  H 
 157 
647392 
 
H H H 
652912 
  
H H 
654089 
 
OH H H 
7349533 
 
  H 
9594283 
 
H 
 
H 
9594287 
 
H 
 
H 
9973697 
 
H 
 
H 
 
 
Appendix Table 8b. A list of compounds for a secondary scaffold in the quinolines library that was screened in 
≥100 bioassays 
 
 158 
CID R1 R2 R3 
16738615 
 
F  
16738637 
 
H 
 
16738642 
 
H 
 
16738659 
   
495051 
 
H H 
 
 
Appendix Table 8c. A list of a secondary scaffold in the quinolines library that was screened in ≥100 bioassays 
 
CID R1 R2 
2882083 
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Appendix Table 8d. A list of compounds for a secondary scaffold in the quinolines library that was screened in 
≥100 bioassays 
 
CID R1 R2 R3 R4 R5 R6 
2882119 
 
 
H H Cl H 
3125599 
 
H H  H  
3136845 
 
H H  H  
646406 
 
H   H H 
 
 
NB: 
• Yollow colored boxes refer to compounds that were excluded after filtering.  
• CIDs followed by ± are compounds with different enantiomeric forms. 
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Appendix Table 9. A list of the shared bioassays; 223 bioassays. 
AID Bioassay 
2690 A yeast HTS for caloric restriction mimetics that inhibit age-related 
superoxide 
2805 uHTS Luminescent assay for identification of activators of mouse 
intestinal alkaline phosphatase 
2806 uHTS Luminescent assay for identification of inhibitors of mouse 
intestinal alkaline phosphatase 
434973 uHTS Luminescent assay for identification of inhibitors of Sentrin-
specific protease 7 (SENP7) 
434989 Fluorescence-based cell-based primary high throughput screening assay 
to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1) 
435022 uHTS luminescence assay for the identification of chemical inhibitors 
of B-cell specific antigen receptor-induced NF-kB activation 
435030 
Absorbance-based primary bacterial cell-based high throughput 
screening assay to identify inhibitors of AddAB recombination protein 
complex 
449763 
uHTS identification of small molecule activators of the apoptotic arm 
of the Unfolded Protein response via a luminescent-based reporter 
assay 
463079 
Fluorescence-based counterscreen for orexin 1 receptor (OX1R) 
antagonists: cell-based assay to identify antagonists of the parental 
CHO cell line 
463082 
Fluorescence polarization-based primary biochemical high throughput 
screening assay to identify inhibitors of the plasma platelet activating 
factor acetylhydrolase (pPAFAH) 
463104 uHTS identification of small molecule activators of the adaptive arm of 
the Unfolded Protein response via a luminescent-based reporter assay 
463141 Absorbance-based primary biochemical high throughput screening 
assay to identify activators of procaspase-3 
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463190 uHTS identification of small molecule inhibitors of tim10-1 yeast via a 
luminescent assay 
463195 uHTS identification of small molecule inhibitors of tim10 yeast via a 
luminescent assay 
463212 uHTS identification of small molecule inhibitors of tim23-1 yeast via a 
luminescent assay 
463254 qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using 
CHOP2 as the Reporter 
485272 
Fluorescence polarization-based primary biochemical high throughput 
screening assay to identify inhibitors of Protein Arginine Deiminase 4 
(PAD4) (1536 HTS) 
485275 Phenotypic HTS multiplex for antifungal efflux pump inhibitors 
485290 qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1) 
485341 qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent) 
485346 uHTS for identification of Inhibitors of Mdm2/MdmX interaction in 
luminescent format. 
485349 qHTS Assay for Identifying a Potential Treatment of Ataxia-
Telangiectasia 
485353 qHTS of Yeast-based Assay for SARS-CoV PLP 
485367 qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase 
488837 qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2 
488839 Development of CDK5 inhibitors   Measured in Biochemical System 
Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity 
488847 RNA aptamer-based HTS for inhibitors of GRK2 
488862 
Inhibitors of Prion Protein 5’ UTR mRNA Measured in Cell-Based 
System Using Plate Reader - 2078-
01_Inhibitor_SinglePoint_HTS_Activity 
488895 High Throughput Screen for Tat Transport Inhibitors Measured in 
Microorganism System Using Plate Reader - 2093-
 162 
01_Inhibitor_SinglePoint_HTS_Activity 
488896 
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells 
Measured in Cell-Based System Using Plate Reader - 2085-
01_Inhibitor_SinglePoint_HTS_Activity 
488899 MITF Measured in Cell-Based System Using Plate Reader - 2084-
01_Inhibitor_SinglePoint_HTS_Activity 
488965 
Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. 
aeruginosa PvdQ acylase Measured in Biochemical System Using Plate 
Reader and Imaging Combination - 2091-
01_Inhibitor_SinglePoint_HTS_Activity 
488966 Primary and Confirmatory Screening for Inhibitors of Bacterial 
Capsule Biogenesis 
489030 uHTS Fluorescent assay for identification of inhibitors of Apaf-1 
489031 uHTS Fluorescent assay for identification of activators of Apaf-1 
492947 qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor 
492953 
Fluorescence polarization-based primary biochemical high throughput 
screening assay to identify inhibitors of human platelet-activating 
factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2) 
492956 
Fluorescence polarization-based primary biochemical high throughput 
screening assay to identify inhibitors of human platelet activating factor 
acetylhydrolase 2 (PAFAH2) 
492972 
Fluorescence polarization-based primary biochemical high throughput 
screening assay to identify inhibitors of human platelet-activating 
factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3) 
493005 qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the 
Interaction of PTAP/TSG101 
493008 
Fluorescence-based biochemical primary high throughput screening 
assay to identify activators of the calcium sensitivity of cardiac 
Regulated Thin Filaments (RTF) 
493011 uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a 
fluorescence-based single-stranded DNA deaminase assay 
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493012 uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a 
fluorescence-based single-stranded DNA deaminase assay 
493014 qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor 
Signaling 
493036 Image-Based HTS for Selective Agonists for NTR1 
493087 
Fluorescence polarization-based cell-based primary high throughput 
screening assay to identify activators of insulin-degrading enzyme 
(IDE) 
493091 uHTS Colorimetric assay for identification of inhibitors of Scp-1 
493098 uHTS identification of small molecule antagonists of the CCR6 
receptor via a luminescent beta-arrestin assay 
493131 
Activator for delta FosB/delta FosB homodimer Measured in 
Biochemical System Using Plate Reader - 2072-
01_Activator_SinglePoint_HTS_Activity 
493160 uHTS Fluorescent assay for identification of inhibitors of hexokinase 
domain containing  I (HKDC1) 
493187 uHTS Fluorescent assay for identification of activators of hexokinase 
domain containing  I (HKDC1) 
493244 
Fluorescence-based biochemical primary high throughput screening 
assay to identify inhibitors of the calcium sensitivity of cardiac 
Regulated Thin Filaments (RTF) 
504326 
Luminescence-based cell-based primary high throughput screening 
assay to identify agonists of heterodimerization of the mu 1 (OPRM1) 
and delta 1 (OPRD1) opioid receptors 
504327 qHTS Assay for Inhibitors of GCN5L2 
504329 Discovery of Small Molecule Probes for H1N1 Influenza NS1A 
504339 qHTS Assay for Inhibitors of JMJD2A-Tudor Domain 
504357 
Luminescence-based cell-based primary high throughput screening 
assay to identify inverse agonists of heterodimerization of the mu 1 
(OPRM1) and delta 1 (OPRD1) opioid receptors 
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504411 
Fluorescence-based primary biochemical high throughput screening 
assay to identify inhibitors of human diacylglycerol lipase, beta 
(DAGLB) 
504423 C-LANA FP assay Measured in Biochemical System Using Plate 
Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity 
504441 Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 
2124-01_Inhibitor_SinglePoint_HTS_Activity 
504444 Nrf2 qHTS screen for inhibitors 
504454 HTS for Beta-2AR agonists via FAP method 
504462 uHTS fluorescent assay for identification of inhibitors of ATG4B 
504466 qHTS screen for small molecules that induce genotoxicity in human 
embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1 
504467 
qHTS screen for small molecules that inhibit ELG1-dependent DNA 
repair in human embryonic kidney (HEK293T) cells expressing 
luciferase-tagged ELG1 
504490 Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction 
That Mediate GPCR Degradation and Recycling 
504523 
Fluorescence polarization to screen for inhibitors that disrupt the 
protein-protein interaction between Keap1 and Nrf2   Measured in 
Biochemical System Using Plate Reader - 2119-
01_Inhibitor_SinglePoint_HTS_Activity 
504558 
Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase 
reporter Measured in Cell-Based System Using Plate Reader - 2122-
01_Inhibitor_SinglePoint_HTS_Activity 
504577 HTS of Small Molecules that Regulate V-ATPase Proton Transport in 
Yeast using pHLuorin 
504582 
In vivo-based yeast HTS to detect compounds rescuing yeast 
growth/survival of Plasmodium Falciparum HSP40-mediated toxicity 
Measured in Whole Organism System Using Plate Reader - 2120-
01_Inhibitor_SinglePoint_HTS_Activity 
504621 Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System 
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Using Plate Reader - 2121-
01_Inhibitor_SinglePoint_HTS_Activity_Set2 
504634 
Counterscreen for inverse agonists of OPRM1-OPRD1 
heterodimerization: luminescence-based cell-based full-deck high 
throughput screening assay to identify inverse agonists of 5-
hydroxytryptamine (serotonin) 5A receptor (HTR5A) 
504690 
uHTS identification of small molecule inhibitors of Plasmodium 
falciparum Glucose-6-phosphate dehydrogenase via a fluorescence 
intensity assay 
504692 
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: 
luminescence-based cell-based full-deck high throughput screening 
assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A 
receptor (HTR5A) 
504700 
Fluorescence polarization-based biochemical primary high throughput 
screening assay to identify activators of the Protein Kinase A-R2B 
(PKA-R2B) complex 
504706 qHTS assay for re-activators of p53 using a Luc reporter 
504707 
Fluorescence polarization-based biochemical primary high throughput 
screening assay to identify activators of the Protein Kinase A-R1A 
(PKA-R1A) complex 
504720 uHTS identification of MazEF TA System activators  via a 
fluorescence-based single-stranded RNase assay 
504734 Fluorescence-based cell-based primary high throughput screening assay 
to identify inhibitors of TLR9-MyD88 binding. 
504766 
Luminescence-based primary cell-based high throughput screening 
assay to identify inhibitors of the orphan nuclear receptor subfamily 0, 
group B, member 1 (DAX1; NR0B1) 
504775 
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells 
Measured in Cell-Based System Using Plate Reader - 2085-
01_Activator_SinglePoint_HTS_Activity 
504803 Fluorescence polarization-based primary biochemical high throughput 
screening assay to identify inhibitors of the HTRA serine peptidase 1 
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(HTRA1) 
504810 Antagonists of the Thyroid Stimulating Hormone Receptor: HTS 
campaign 
504812 Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS 
campaign 
504842 Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus 
maripaludis (MmCpn): qHTS 
504845 Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS 
504847 Inhibitors of the vitamin D receptor (VDR): qHTS 
504884 
Inhibitors of Y. pestis Topo-I using cleavage product accumulation 
Measured in Biochemical System Using Plate Reader - 2123-
01_Inhibitor_SinglePoint_HTS_Activity 
504891 qHTS Assay to Find Inhibitors of Pin1 
504894 Activators of T cell receptors: qHTS campaign 
540253 qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated 
importin-beta cargo) - Importin beta complex dissociation 
540263 qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta 
cargo) - Importin beta complex formation 
540267 Small Molecules that selectively kill Giardia lamblia: qHTS 
540295 
TRFRET-based cell-based primary high throughput screening assay to 
identify biased ligands of the melanocortin 4 receptor (MC4R): 
antagonists of MC4R 
540303 qHTS for Inhibitors of Cell Surface uPA Generation 
540308 
Luminescence-based cell-based primary high throughput screening 
assay to identify biased ligands of the melanocortin 4 receptor (MC4R): 
agonists of MC4R 
540317 HTS for Inhibitors of HP1-beta Chromodomain Interactions with 
Methylated Histone Tails 
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540336 Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 
2106-01_Inhibitor_SinglePoint_HTS_Activity 
540364 Luminescence-based cell-based primary high throughput screening 
assay to identify activators of the GAA850 frataxin (FXN) promoter 
588334 MITF Measured in Cell-Based System Using Plate Reader - 2084-
01_Activator_SinglePoint_HTS_Activity 
588335 
Counterscreen for inhibitors of the fructose-bisphosphate aldolase 
(FBA) of M. tuberculosis: Absorbance-based biochemical high 
throughput Glycerophosphate Dehydrogenase-Triosephosphate 
Isomerase (GDH-TPI) full deck assay to identify assay artifacts 
588352 
Luminescence-based cell-based primary high throughput screening 
assay to identify inhibitors of the Steroid Receptor Coactivator 3 
(SRC3; NCOA3) 
588354 
Luminescence-based cell-based primary high throughput screening 
assay to identify inhibitors of the Steroid Receptor Coactivator 1 
(SRC1; NCOA1) 
588358 HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies 
588391 
Turbidometric Biochemical  Primary HTS  to identify inhibitors of 
Protein Disulfide Isomerase Measured in Biochemical System Using 
Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity 
588405 HTS Assay for Peg3 Promoter Inhibitors 
588413 uHTS identification of Gli-Sufu Antagonists in a luminescence reporter 
assay 
588436 
Cholera Quorum: HTS for inducers of light production in the absence 
ofautoinducers using BH1578 (luxS deficient, cqsA deficient) 
Measured in Microorganism System Using Plate Reader - 2132-
01_Agonist_SinglePoint_HTS_Activity 
588453 qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin 
Reductase 1 (TrxR1): qHTS 
588456 qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin 
Reductase 1 (TrxR1): qHTS 
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588458 uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular 
Beacon assay 
588473 uHTS identification of agonists of the CRF-binding protein and CRF-
R2 receptor complex 
588475 uHTS identification of antagonists of the CRF-binding protein and 
CRF-R2 receptor complex 
588478 A screen for small molecule inhibitors of the human deubiquitinating 
enzyme, UCH37 
588489 uHTS identification of microRNA-mediated mRNA deadenylation 
inhibitors by fluoresence polarization assay 
588492 uHTS identification of small molecule modulators of myocardial 
damage 
588493 uHTS identification of inhibitors of Rpn11 in a Fluorescent 
Polarization assay 
588497 
High-throughput multiplex microsphere screening for inhibitors of 
toxin protease, specifically Botulinum neurotoxin light chain F 
protease, MLPCN compound set 
588499 
High-throughput multiplex microsphere screening for inhibitors of 
toxin protease, specifically Botulinum neurotoxin light chain A 
protease, MLPCN compound set 
588501 
High-throughput multiplex microsphere screening for inhibitors of 
toxin protease, specifically Lethal Factor Protease, MLPCN compound 
set 
588549 
Fluorescence polarization to screen for inhibitor that competite the 
binding of FadD28 to bisubstrate Measured in Biochemical System 
Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity 
588579 qHTS for Inhibitors of Polymerase Kappa 
588590 qHTS for Inhibitors of Polymerase Iota 
588591 qHTS for Inhibitors of Polymerase Eta 
588621 uHTS identification of small molecule inhibitors of Striatal-Enriched 
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Phosphatase via a fluorescence intensity assay 
588664 
TRFRET-based biochemical primary high throughput screening assay 
to identify inhibitors of the interaction of the Ras and Rab interactor 1 
protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase 
(Abl) 
588674 
Schnurri-3 Inhibitors: specific inducers of adult bone formation 
Measured in Cell-Based System Using Plate Reader - 2134-
01_Inhibitor_SinglePoint_HTS_Activity_Set2 
588689 Primary and Confirmatory Screening for Flavivirus Genomic Capping 
Enzyme Inhibition 
588692 
Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked 
Glycosylation Measured in Cell-Based System Using Plate Reader - 
2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2 
588727 A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, 
TC-83 
588795 qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). 
588814 
Fluorescence-based cell-based primary high throughput screening assay 
to identify agonists of the human cholinergic receptor, muscarinic 1 
(CHRM1) 
588819 
Fluorescence-based cell-based primary high throughput screening assay 
to identify positive allosteric modulators (PAMs) of the human M1 
muscarinic receptor (CHRM1). 
588852 Fluorescence-based cell-based primary high throughput screening assay 
to identify antagonists of the human M1 muscarinic receptor (CHRM1) 
588855 qHTS for Inhibitors of TGF-b 
602123 
Fluorescence polarization-based primary biochemical high throughput 
screening assay to identify inhibitors of Escherichia coli DNA-binding 
ATP-dependent protease La (eLon) 
602141 uHTS determination of small molecule cytotoxicity in a fluorescence 
assay to identify cystic fibrosis induced NFkb Inhibitors 
602162 Flow Cytometric HTS Screen for inhibitors of the ABC transporter 
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ABCB6 for MLPCN Compound Set 
602163 
Absorbance-based biochemical primary high throughput screening 
assay to identify activators of Methionine sulfoxide reductase A 
(MsrA) 
602179 qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): 
qHTS 
602229 
Luminescence-based cell-based high throughput primary screening 
assay to identify agonists of nuclear receptor subfamily 2, group E, 
member 3 (NR2E3) 
602233 qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase 
602244 uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence 
assay 
602247 
Full deck counterscreen for positive allosteric modulators (PAMs) of 
the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-
based high throughput screening assay to identify nonselective 
activators and assay artifacts using the parental CHOK1 cell line 
602248 
Full deck counterscreen for agonists of the human M1 muscarinic 
receptor (CHRM1): Fluorescence-based cell-based high throughput 
screening assay to identify nonselective activators and assay artifacts 
using the parental CHOK1 cell line 
602250 
Full deck counterscreen for antagonists of the human M1 muscarinic 
receptor (CHRM1): Fluorescence-based cell-based high throughput 
screening assay to identify nonselective inhibitors and assay artifacts 
using the parental CHOK1 cell line 
602252 
Fluorescence Polarization with CAL-PDZ Measured in Biochemical 
System Using Plate Reader - 2109-
02_Inhibitor_SinglePoint_HTS_Activity 
602261 uHTS identification of small molecule inhibitors of  the thioesterase 
domain of fatty acid synthase via a fluorescence intensity assay 
602274 
uHTS luminescent assay for identification of compounds that enhance 
the survival of human induced pluripotent stem cells when cultured as 
single cells 
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602281 
Luminescence-based biochemical primary high throughput screening 
assay to identify inhibitors of the interaction of the lipase co-activator 
protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 
(MLDP; PLIN5) 
602310 qHTS for Inhibitors of Vif-A3G Interactions: qHTS 
602313 qHTS for Inhibitors of Vif-A3F Interactions: qHTS 
602329 Identification of inhibitors of RAD54 Measured in Biochemical System 
Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity 
602332 qHTS for Inducers of the Endoplasmic Reticulum Stress Response 
(ERSR) in Human Glioma: qHTS 
602340 
HTS for suppressors of simvastatin-induced mytoxicity in 
differentiated C2C12 cells Measured in Cell-Based System Using Plate 
Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity 
602342 Small molecule inhibitors of miR122  Measured in Cell-Based System 
Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity 
602346 Identification of VIF Inhibitors Measured in Cell-Based System Using 
Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity 
602363 
Whole cell Yeast HTS to identify compounds modulating the fidelity of 
the start codon recognition in eukaryotes. Measured in Whole 
Organism System Using Plate Reader - 2155-
01_Other_SinglePoint_HTS_Activity 
602393 
Screen for inhibitors of the SWI/SNF chromatin remodeling complex 
(esBAF) in mouse embryonic stem cells with Luciferase reporter assay 
Measured in Cell-Based System Using Plate Reader - 2141-
01_Inhibitor_SinglePoint_HTS_Activity 
602396 
Luminescence-based cell-based primary high throughput screening 
assay to identify inverse agonists of the liver receptor homolog-1 
(LRH-1; NR5A2) 
602399 uHTS identification of inhibitors of NadD in a Colorimetric assay 
602405 PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in 
Biochemical System Using Plate Reader - 2164-
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01_Inhibitor_SinglePoint_HTS_Activity 
602410 Primary cell-based screen for identification of compounds that inhibit 
the two-pore domain potassium channel KCNK3 
602429 uHTS identification of SUMO1-mediated protein-protein interactions 
602438 uHTS identification of modulators of interaction between CendR and 
NRP-1 using Fluorescence Polarization assay 
602440 uHTS Fluorescent Assay Using Nedd8 Protein Substrate for 
Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8) 
602449 uHTS identification of small molecule inhibitors of the mitochondrial 
permeability transition pore via an absorbance assay 
602481 
Mycobacterium tuberculosis BioA enzyme inhibitor Measured in 
Biochemical System Using Plate Reader - 2163-
01_Inhibitor_SinglePoint_HTS_Activity 
623870 
ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 
interactions Measured in Biochemical System Using Plate Reader - 
2158-01_Inhibitor_SinglePoint_HTS_Activity 
623877 
Primary cell-based high-throughput screening for identification of 
compounds that activate/potentiate calcium-activated chloride channels 
(TMEM16A) 
623901 Small molecule inhibitors of miR122  Measured in Cell-Based System 
Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity 
624037 
Fluorescence-based cell-based primary high throughput screening assay 
to identify agonists of the human cholinergic receptor, muscarinic 5 
(CHRM5) 
624038 
Fluorescence-based cell-based primary high throughput screening assay 
to identify positive allosteric modulators (PAMs) of the human 
cholinergic receptor, muscarinic 5 (CHRM5) 
624040 
Fluorescence-based cell-based primary high throughput screening assay 
to identify antagonists of the human cholinergic receptor, muscarinic 5 
(CHRM5) 
624125 Fluorescence-based cell-based primary high throughput screening assay 
to identify antagonists of the human cholinergic receptor, muscarinic 4 
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(CHRM4) 
624126 
Fluorescence-based cell-based primary high throughput screening assay 
to identify positive allosteric modulators (PAMs) of the human 
cholinergic receptor, muscarinic 4 (CHRM4) 
624127 
Fluorescence-based cell-based primary high throughput screening assay 
to identify agonists of the human cholinergic receptor, muscarinic 4 
(CHRM4) 
624168 uHTS identification of small molecule activators of alpha dystroglycan 
glycosylation 
624169 
Luminescence-based cell-based primary high throughput screening 
assay to identify agonists of the mouse 5-hydroxytryptamine 
(serotonin) receptor 2A (HTR2A) 
624170 qHTS for Inhibitors of Glutaminase (GLS) 
624171 qHTS of Nrf2 Activators 
624172 qHTS of GLP-1 Receptor Agonists 
624173 qHTS of Trypanosoma Brucei Inhibitors 
624178 qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native 
Substrate 
624202 qHTS Assay to Identify Small Molecule Activators of BRCA1 
Expression 
624204 uHTS identification of small molecule inhibitors of the catalytic 
domain of the SUMO protease, SENP1 in a FRET assay 
624246 qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction 
624256 HTS to identify compounds that promote myeloid differentiation with 
MLPCN compound set 
624263 A Quantitative High throughput Screen to Identify Chemical 
Modulators of PINK1 Expression 
624267 
Fluorescence-based cell-based primary high throughput screening assay 
to identify inhibitors of the interaction of nucleotide-binding 
oligomerization domain containing 2 (NOD2) and the receptor-
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interacting serine-threonine kinase 2 (RIPK2) 
624268 
Luminescence-based biochemical primary high throughput screening 
assay to identify inhibitors of Trypanosoma brucei methionyl tRNA 
synthetase (MetRS) 
624288 qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for 
Fibrous Dysplasia/McCune-Albright Syndrome: qHTS 
624291 qHTS for Activators of Integrin-Mediated Alleviation for Muscular 
Dystrophy 
624296 A quantitative high throughput screen for small molecules that induce 
DNA re-replication in MCF 10a normal breast cells. 
624304 uHTS identification of SKN-1 Inhibitors in a fluoresence assay 
624330 Discovery of small molecule inhibitors of the oncogenic and 
cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens 
624352 uHTS identification of HIF-2a Inhibitors in a luminesence assay 
624354 uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence 
assay 
624377 
Fluorescence polarization-based biochemical primary high throughput 
screening assay to identify inhibitors of ArfGAP with SH3 domain, 
ankyrin repeat and PH domain 1 (ASAP1) 
624414 qHTS for Agonists of the Human Mucolipin Transient Receptor 
Potential 1 (TRPML1) 
624415 qHTS for Inhibitors of the Human Mucolipin Transient Receptor 
Potential 1 (TRPML1) 
624416 
TRFRET-based biochemical primary high throughput screening assay 
to identify small molecules that bind to the HIV-1-gp120 binding 
antibody, PG9 
624417 qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) 
624463 Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 
Dopamine Receptor: Antagonists 
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624464 Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 
Dopamine Receptor: Potentiators 
624465 
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 
Dopamine Receptor: Agonists 
624466 
Fluorescence-based cell-based primary high throughput screening assay 
to identify antagonists of the human trace amine associated receptor 1 
(TAAR1) 
624467 
Fluorescence-based cell-based primary high throughput screening assay 
to identify agonists of the human trace amine associated receptor 1 
(TAAR1) 
624483 
Counterscreen of compound fluorescence effects on High-throughput 
multiplex microsphere screening for inhibitors of toxin protease 
651550 HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen 
651560 
uHTS identification of small molecule inhibitors of Low Molecular 
Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence 
intensity assay 
651572 
Fluorescence polarization-based biochemical primary high throughput 
screening assay to identify inhibitors of ADP-ribosylation factor 
GTPase activating protein 1 (ARFGAP1) 
651582 
uHTS identification of small molecule Triacylglycerol inhbitors in a 
fluoresence assay 
651602 
Absorbance-based primary bacterial cell-based high throughput 
screening assay to identify inhibitors of RecBCD (with phage) 
651610 
HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System 
Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity 
651635 qHTS for Inhibitors of ATXN expression 
651636 
uHTS identification of small molecule antagonists of the EBI2 receptor 
via a luminescent beta-arrestin assay 
651640 
DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism 
Combination System Using Plate Reader - 2149-
01_Other_SinglePoint_HTS_Activity 
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651644 qHTS Assay for Inhibitors of the HIV-1 protein Vpr 
651647 
uHTS identification of inhibitors of MT1-MMP activation in a 
fluoresence assay 
651654 
HTS for the detection of C. neoformans cell lysis via adenylate kinase 
(AK) release Measured in Microorganism System Using Plate Reader - 
2162-01_Inhibitor_SinglePoint_HTS_Activity 
651658 
Small Molecule Inhibitors of FGF22-Mediated Excitatory 
Synaptogenesis & Epilepsy Measured in Biochemical System Using 
RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity 
651687 
MLPCN PGC1a Modulators Measured in Cell-Based System Using 
Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity 
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Appendix Figure 1.  Graph A represents the number of active bioassays for individual compounds in the 
UPCMLD02A library. Graph B demonstrates that compounds tested in less than 100 bioassays were filtered out and 
that only the shared 223 bioassays were included in the analysis. 
A 
B 
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Appendix Figure 2.  Graph A represents the number of active bioassays for individual compounds in the 
UPCMLD16A library. Graph B demonstrates that compounds tested in less than 100 bioassays were filtered out and 
that only the shared 223 bioassays were included in the analysis. 
A 
B 
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Appendix Figure 3.  Graph A represents the number of active bioassays for individual compounds in the 
UPCMLD24A library. Graph B demonstrates that compounds tested in less than 100 bioassays were filtered out and 
that only the shared 223 bioassays were included in the analysis. 
A 
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Appendix Figure 4.  Graph A represents the number of active bioassays for individual compounds in the 
benzodiazebine scaffold library. Graph B demonstrates that compounds tested in less than 100 bioassays were 
filtered out and that only the shared 223 bioassays were included in the analysis. 
A 
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Appendix Figure 5.  Graph A represents the number of active bioassays for individual compounds in the 
dihydropyridine scaffold library. Graph B demonstrates that compounds tested in less than 100 bioassays were 
filtered out and that only the shared 223 bioassays were included in the analysis. 
A 
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Appendix Figure 6.  Graph A represents the number of active bioassays for individual compounds in the rhodanine 
scaffold library. Graph B demonstrates that compounds tested in less than 100 bioassays were filtered out and that 
only the shared 223 bioassays were included in the analysis. 
A 
B 
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Appendix Figure 7.  Graph A represents the number of active bioassays for individual compounds in the quinoline 
scaffold library. Graph B demonstrates that compounds tested in less than 100 bioassays were filtered out and that 
only the shared 223 bioassays were included in the analysis. 
A
B 
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